MiMedx Group, Inc (NASDAQ:MDXG) Receives Consensus Recommendation of “Moderate Buy” from Analysts

by · The Markets Daily

Shares of MiMedx Group, Inc (NASDAQ:MDXG – Get Free Report) have been given a consensus rating of “Moderate Buy” by the seven brokerages that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $8.50.

MDXG has been the topic of a number of recent analyst reports. Craig Hallum cut their price target on shares of MiMedx Group from $10.00 to $7.00 and set a “buy” rating on the stock in a report on Friday, April 17th. Citizens Jmp cut their price target on shares of MiMedx Group from $7.00 to $6.00 and set a “market outperform” rating on the stock in a report on Thursday, April 30th. Wall Street Zen lowered shares of MiMedx Group from a “buy” rating to a “hold” rating in a report on Saturday, May 2nd. Weiss Ratings lowered shares of MiMedx Group from a “sell (d+)” rating to a “sell (d)” rating in a report on Monday, May 18th. Finally, UBS Group set a $10.00 price target on shares of MiMedx Group in a report on Monday, February 23rd.

View Our Latest Analysis on MDXG

MiMedx Group Stock Down 0.3%

MDXG stock opened at $3.57 on Wednesday. MiMedx Group has a 12 month low of $3.03 and a 12 month high of $7.99. The firm has a market cap of $531.75 million, a PE ratio of 17.85 and a beta of 1.48. The firm has a 50 day simple moving average of $3.68 and a 200 day simple moving average of $5.12. The company has a debt-to-equity ratio of 0.07, a current ratio of 5.39 and a quick ratio of 4.81.

MiMedx Group (NASDAQ:MDXG – Get Free Report) last released its quarterly earnings results on Wednesday, April 29th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.02. MiMedx Group had a net margin of 7.88% and a return on equity of 21.03%. The business had revenue of $58.99 million for the quarter, compared to analyst estimates of $65.80 million. Equities research analysts forecast that MiMedx Group will post -0.01 earnings per share for the current fiscal year.

Institutional Investors Weigh In On MiMedx Group

A number of large investors have recently made changes to their positions in the company. Royal Bank of Canada increased its stake in MiMedx Group by 1.4% in the 1st quarter. Royal Bank of Canada now owns 982,532 shares of the company’s stock valued at $7,466,000 after buying an additional 13,629 shares during the period. AQR Capital Management LLC increased its stake in MiMedx Group by 42.6% in the 1st quarter. AQR Capital Management LLC now owns 14,374 shares of the company’s stock valued at $109,000 after buying an additional 4,296 shares during the period. Jacobs Levy Equity Management Inc. acquired a new position in MiMedx Group in the 1st quarter valued at approximately $232,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in MiMedx Group by 5.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 73,518 shares of the company’s stock valued at $559,000 after buying an additional 4,049 shares during the period. Finally, Millennium Management LLC increased its stake in MiMedx Group by 93.9% in the 1st quarter. Millennium Management LLC now owns 1,230,984 shares of the company’s stock valued at $9,355,000 after buying an additional 596,016 shares during the period. Institutional investors and hedge funds own 79.15% of the company’s stock.

MiMedx Group Company Profile

(Get Free Report)

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.

See Also